P
Phase
3D printing platform for microfluidics, enabling biomimicry and non-engineer design for next-gen therapeutics
About Phase
Phase, Inc. is at the forefront of the microfluidics industry with its advanced 3D printing platform designed to revolutionize the $17 billion market. The company specializes in creating microfluidic devices, which are essential for developing next-generation therapeutics and diagnostics. These devices serve as the digital age's test tubes, facilitating groundbreaking medical research. Phase, Inc. employs proprietary LE3D printing technology that offers unmatched biomimicry, using biocompatible materials not currently 3D printable by competitors. This technology is complemented by a user-friendly interface that allows non-engineers to design and create microfluidics with ease. The company is backed by an NIH grant and collaborates with the Virginia Tech Wake Forest School of Biomedical Engineering and Sciences to develop microfluidic devices for brain cancer treatment research. Phase, Inc. operates in the biomedical engineering sector, serving researchers and scientists focused on medical breakthroughs. Its business model revolves around leveraging its unique 3D printing capabilities to provide cutting-edge solutions in microfluidics, generating revenue through partnerships and grants.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cornelius, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 68.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, 3D Printing, Biotechnology, Microfluidics, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2025 | $13M | $52M | WI Harper Group · 500 Global · Shilling VC · SquareOne | ↗ |
| GRANT✓Other financing | Feb 2024 | $1.8M | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Phase is 580 monthly website visits, down 84.3% over the last three months. Phase's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institutes of Health
National Center For Advancing Translational Sciences
First Flight Venture Center
Series A7 investors entered at this stage
WI Harper Group
500 Global
Shilling VC
SquareOne
Palm Drive Capital
Gobi Partners
42CAP
Series B and later1 investor entered at this stage
North Carolina Biotechnology Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phase on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phase’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.